What is the general recommended age to start receiving the recombinant zoster vaccine?

The general recommended age to start receiving the recombinant zoster vaccine, known as Shingrix, is 50 years. This recommendation is based on research indicating that the incidence of herpes zoster, or shingles, increases significantly after this age. The vaccine is designed to boost the immune response and reduce the risk of shingles and its complications, such as postherpetic neuralgia, which can significantly impair quality of life. By vaccinating individuals around 50, it aims to provide protection before the risk increases substantially.

Receiving the vaccine before age 50 may not provide maximum effectiveness, as the immune system's response typically begins to decline with age, making it essential to initiate vaccination at the recommended age. Those older than 50, especially those with certain risk factors, should also be encouraged to get vaccinated to maintain effective immunity against the virus.